NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $23.58 -0.02 (-0.08%) Closing price 04:00 PM EasternExtended Trading$23.40 -0.18 (-0.76%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nurix Therapeutics Stock (NASDAQ:NRIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$22.91▼$23.9050-Day Range$14.64▼$24.6952-Week Range$8.19▼$25.08Volume1.25 million shsAverage Volume1.52 million shsMarket Capitalization$2.45 billionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology. The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies. Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches. Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.AI Generated. May Contain Errors. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreNRIX MarketRank™: Nurix Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 551st out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNurix Therapeutics has a consensus price target of $34.00, representing about 44.2% upside from its current price of $23.58.Amount of Analyst CoverageNurix Therapeutics has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nurix Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.57% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 13.87, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 1.02%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.14 News SentimentNurix Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nurix Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $590,925.00 in company stock.Percentage Held by Insiders6.70% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by InstitutionsNurix Therapeutics has minimal institutional ownership at this time.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRIX Stock News HeadlinesNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across ...July 21, 2026 | markets.businessinsider.comNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and NeurologyJuly 21, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 30 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Axsome Therapeutics (AXSM) and Nurix Therapeutics (NRIX)July 15, 2026 | theglobeandmail.comOppenheimer Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)July 11, 2026 | theglobeandmail.comNurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateJuly 10, 2026 | finanznachrichten.deNurix Therapeutics Q2 2026 EarningsJuly 9, 2026 | 247wallst.comNurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateJuly 9, 2026 | globenewswire.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.97 at the beginning of the year. Since then, NRIX shares have increased by 24.3% and is now trading at $23.58. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Thursday, July, 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by $0.08. The company had revenue of $9.04 million for the quarter, compared to analysts' expectations of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative trailing twelve-month return on equity of 76.09%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $187 million in an IPO on Friday, July 24th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Nurix Therapeutics' top institutional investors include Handelsbanken Fonder AB (0.61%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van and Christine Ring. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V). Company Calendar Last Earnings7/09/2026Today7/30/2026Next Earnings (Estimated)10/08/2026Fiscal Year End11/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NRIX's financial health is in the Green zone, according to TradeSmith. NRIX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year Founded2012Price Target and Rating Average Price Target for Nurix Therapeutics$34.00 High Price Target$45.00 Low Price Target$25.00 Potential Upside/Downside+44.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($3.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$264.46 million Net Margins-928.44% Pretax Margin-929.18% Return on Equity-76.09% Return on Assets-57.31% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$83.98 million Price / Sales29.14 Cash FlowN/A Price / Cash FlowN/A Book Value$3.88 per share Price / Book6.08Miscellaneous Outstanding Shares103,780,000Free Float96,829,000Market Cap$2.45 billion OptionableOptionable Beta1.80 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NRIX) was last updated on 7/30/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
